Statistics for Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial
Total visits
| views | |
|---|---|
| Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial | 4 |
Total visits per month
| views | |
|---|---|
| October 2024 | 0 |
| November 2024 | 0 |
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 0 |
| March 2025 | 0 |
| April 2025 | 0 |
File Visits
| views | |
|---|---|
| java.util.UUID:4f8a344a-f764-48c8-82c6-d05f19a3d34f | 38 |
| java.util.UUID:bef93abd-df11-4458-a853-5fd1ee5fc4f7 | 12 |
| Boni2022Praluzatamab-CCBYNCND.pdf | 10 |
| java.util.UUID:7aee6609-848e-4a26-ad96-11227b5af6fd | 5 |
Top country views
| views | |
|---|---|
| United States | 3 |
| India | 1 |
Top city views
| views | |
|---|---|
| Indianapolis | 2 |
| Greenwood | 1 |
| Pune | 1 |